98 related articles for article (PubMed ID: 28175331)
1. Long-term survivors of primary central nervous system lymphoma.
Yamanaka R; Morii K; Sano M; Homma J; Yajima N; Tsukamoto Y; Ogura R; Natsumeda M; Aoki H; Akiyama K; Saitoh T; Hondoh H; Kawaguchi A; Takahashi H; Fujii Y
Jpn J Clin Oncol; 2017 Feb; 47(2):101-107. PubMed ID: 28175331
[TBL] [Abstract][Full Text] [Related]
2. Cognitive functions in survivors of primary central nervous system lymphoma.
Correa DD; DeAngelis LM; Shi W; Thaler H; Glass A; Abrey LE
Neurology; 2004 Feb; 62(4):548-55. PubMed ID: 14981169
[TBL] [Abstract][Full Text] [Related]
3. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.
Guha-Thakurta N; Damek D; Pollack C; Hochberg FH
J Neurooncol; 1999 Jul; 43(3):259-68. PubMed ID: 10563432
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.
Juergens A; Pels H; Rogowski S; Fliessbach K; Glasmacher A; Engert A; Reiser M; Diehl V; Vogt-Schaden M; Egerer G; Schackert G; Reichmann H; Kroschinsky F; Bode U; Herrlinger U; Linnebank M; Deckert M; Fimmers R; Schmidt-Wolf IG; Schlegel U
Ann Neurol; 2010 Feb; 67(2):182-9. PubMed ID: 20225195
[TBL] [Abstract][Full Text] [Related]
7. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
[TBL] [Abstract][Full Text] [Related]
8. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive outcomes in primary CNS lymphoma (PCNSL).
O'Neill BP
Neurology; 2004 Feb; 62(4):532-3. PubMed ID: 14981164
[No Abstract] [Full Text] [Related]
10. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
11. Complete response to therapy: why do primary central nervous system lymphoma patients not return to work?
Wiemann G; Pertz M; Kowalski T; Seidel S; Schlegel U; Thoma P
J Neurooncol; 2020 Aug; 149(1):171-179. PubMed ID: 32737735
[TBL] [Abstract][Full Text] [Related]
12. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
Ney DE; Reiner AS; Panageas KS; Brown HS; DeAngelis LM; Abrey LE
Cancer; 2010 Oct; 116(19):4605-12. PubMed ID: 20572045
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.
Gavrilovic IT; Hormigo A; Yahalom J; DeAngelis LM; Abrey LE
J Clin Oncol; 2006 Oct; 24(28):4570-4. PubMed ID: 17008697
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
16. Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.
Farhi J; Laribi K; Orvain C; Hamel JF; Mercier M; Sutra Del Galy A; Clavert A; Rousselet MC; Tanguy-Schmidt A; Hunault-Berger M; Moles-Moreau MP
Ann Hematol; 2018 Dec; 97(12):2391-2401. PubMed ID: 30091022
[TBL] [Abstract][Full Text] [Related]
17. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
[TBL] [Abstract][Full Text] [Related]
18. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system lymphoma: from clinical presentation to diagnosis.
Herrlinger U; Schabet M; Bitzer M; Petersen D; Krauseneck P
J Neurooncol; 1999 Jul; 43(3):219-26. PubMed ID: 10563426
[TBL] [Abstract][Full Text] [Related]
20. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
